No abstract

Treatment with adriamycin (ADM) and bleomycin (BLEO) alone and in combination has been evaluated in 56 patients with a variety of advanced stage gynecologic cancers. ADM has a high degree of antitumor activity against uterine sarcomas (leiomyosarcoma and stromal sarcoma) and some of the unusual ovarian cancers including ovarian teratoma. ADM was also active and gave clinically worthwhile responses against squamous cell carcinoma of the cervix and vagina. Occasional objective remissions were seen in patients with epithelial ovarian adenocarcinomas. The combination of ADM plus BLEO appeared to show no enhancement of the effect achieved by ADM alone. There were no objective responses in patients with squamous cell carcinoma of the cervix treated with BLEO alone. The usual toxic manifestations of ADM and BLEO were observed, and there appeared to be no potentiation of the toxicity of each agent when used in combination. It is concluded that ADM is a valuable chemotherapeutic agent for certain gynecologic cancers which are usually refractory to other chemotherapeutic agents. Further investigation of its use alone and in combination with other drugs is indicated.

No abstract

No abstract

The risk factors for colon cancer recurrence following a curative intent surgery include the presence of metastatic disease, the tumor location and size, number of positive lymph nodes, the presence of adhesions, perforation, bowel obstruction, depth of invasion, histological grade, percentage of S-phase content, and cell kinetic profile.The DNA content of colon cancers in 20 Dukes' B2 patients in follow-up evaluation at our center, who relapsed, either locally or systemically following surgical treatment was measured by image analysis. The data were pair-matched for age, sex, tumor site, and grade with 20 Dukes' B2 patients who had no evidence of disease.Aneuploidy occurred in 16 (80%) patients with recurrence, as compared with only in 8 (40%) in the control group. Aneuploidy was associated with significantly higher tumor recurrence rate (P = 0.024) and shorter overall survival (P < 0.002).Our data may point out a possible indication for systemic adjuvant chemotherapy in Dukes' B2 colon cancer patients who have aneuploid tumors on image analysis. This warrants further investigation in a prospective controlled randomized study. 0 1995 Wiley-Liss, Inc.

No abstract

No abstract

Adriamycin, a new cytotoxic antibiotic with antitumor activity in a variety of neoplasms, was given to 31 patients with advanced bronchogenic carcinoma. The doses used were 30 and 35 mg/m2 of body surface area daily for 3 days repeated at 3‐ or 4‐week intervals. Objective regression (<50%) was seen in 4 of 20 patients receiving 30 mg/m2 and 5 of 11 patients receiving 35 mg/m2. Regressions according to histologic cell type were seen in 5 of 17 adenocarcinomas, 3 of 6 small cell carcinomas, 1 of 6 large cell anaplastic carcinomas, and 0 of 2 squamous cell carcinomas. Those patients who attained tumor regression survived longer than those who had progression. Toxic manifestations of Adriamycin administration were myelosuppression, stomatitis, cardiomyopathy, and nausea and vomiting. Adriamycin at doses below the cumulative cardiotoxic threshold appears to be of clinical value in advanced bronchogenic carcinoma.